[Malignancy-associated hypercalcemia].
Nihon Rinsho. 2003 Jun; 61(6):1006-9.NR

Abstract

Bisphosphonates (BPs) constitute a major advance in the treatment of malignancy-associated hypercalcemia(MAH). BPs correct MAH through the mechanisms of inhibition of osteoclastic bone resorption. Although BPs are more potent agents than calcitonin in the treatment of MAH, anti-hypercalcemic effect of BPs appears more slowly than that of calcitonin. Therefore, combination therapy with BP and calcitonin is favorable in the treatment of MAH showing hypercalcemic crisis. Zoledronate, most potent bisphosphonate, is apparently superior to pamidronate, standard bisphosphonate, in the treatment of MAH. BP therapy develops no serious adverse effects (i.e. acute renal failure) in clinical practice. However, attention should be paid to BP-induced pyrexia and transient pain increase.

Authors+Show Affiliations

Oura S

Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University.

MeSH

DiphosphonatesHumansHypercalcemiaParaneoplastic Syndromes

Pub Type(s)

English Abstract

Journal Article

Review

Language

jpn

PubMed ID

12806951

Citation

Oura, Shoji. "[Malignancy-associated Hypercalcemia]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 61, no. 6, 2003, pp. 1006-9.

Oura S. [Malignancy-associated hypercalcemia]. Nihon Rinsho. 2003;61(6):1006-9.

Oura, S. (2003). [Malignancy-associated hypercalcemia]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 61(6), 1006-9.

Oura S. [Malignancy-associated Hypercalcemia]. Nihon Rinsho. 2003;61(6):1006-9. PubMed PMID: 12806951.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - [Malignancy-associated hypercalcemia]. A1 - Oura,Shoji, PY - 2003/6/17/pubmed PY - 2003/7/26/medline PY - 2003/6/17/entrez SP - 1006 EP - 9 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nihon Rinsho VL - 61 IS - 6 N2 - Bisphosphonates (BPs) constitute a major advance in the treatment of malignancy-associated hypercalcemia(MAH). BPs correct MAH through the mechanisms of inhibition of osteoclastic bone resorption. Although BPs are more potent agents than calcitonin in the treatment of MAH, anti-hypercalcemic effect of BPs appears more slowly than that of calcitonin. Therefore, combination therapy with BP and calcitonin is favorable in the treatment of MAH showing hypercalcemic crisis. Zoledronate, most potent bisphosphonate, is apparently superior to pamidronate, standard bisphosphonate, in the treatment of MAH. BP therapy develops no serious adverse effects (i.e. acute renal failure) in clinical practice. However, attention should be paid to BP-induced pyrexia and transient pain increase. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/12806951/[Malignancy_associated_hypercalcemia]_ DB - PRIME DP - Unbound Medicine ER -

Tags

[Malignancy-associated hypercalcemia].Nihon Rinsho. 2003 Jun; 61(6):1006-9.NR